EN DE

PT Mitra Keluarga Karyasehat Tbk, (MIKA) Fair Value & Analysis

Healthcare · ID · Market cap 23.7T IDR

PM PT Mitra Keluarga Karyasehat Tbk, MIKA · JK
Price1,890 IDR
Fair Value2,143 IDR
Upside+13.4%
Quality71/100
Watch PT Mitra Keluarga Karyasehat Tbk, for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Highly profitable · 25.3% net margin
Low debt · generates free cash flow
Ranks above peers (10/15)
Wide moat 80/100
Evidence: Medium Range 1,292 IDR – 2,699 IDR Share as image

Fair value as of: Jul 12, 2026

From 26 valuation models · updated 28 days ago

Fair value updated Jul 12, 2026, revised from 2,095 IDR to 2,143 IDR (+2.3%) since Jun 24, 2026. Share price +11.2% over the past month.

A solid business, screening 13% undervalued on our models.

What matters now

  • A fairly wide model range (1,292 IDR to 2,699 IDR) leaves room in how you read the outcome.
  • Our model range runs from 1,292 IDR (bear) to 2,699 IDR (bull), base 2,143 IDR. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 71/100 (solid quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

3,128 IDR 1,396 IDR Fair Value 2,143 IDR Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range 1,396 IDR – 3,128 IDR · fair‑value band 1,292 IDR – 2,699 IDR · the 1,890 IDR price screens below the 2,143 IDR fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PT Mitra Keluarga Karyasehat Tbk, (MIKA) currently trades at 1,890 IDR, while our model-based Fair Value estimate is 2,143 IDR, implying the stock looks roughly 13.4% undervalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, PT Mitra Keluarga Karyasehat Tbk, generated revenue of 5.5T IDR at a net margin of 25.3%. Revenue grew 6.6% year over year. It earns a return on equity of 18.0%. The balance sheet holds a net cash position of 2.5T IDR. Fundamentals as of Jul 12, 2026

Our scenario range runs from 1,292 IDR (bear case) to 2,699 IDR (bull case); at 1,890 IDR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 13%, MIKA screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF 1,083 IDR 1,739 IDR 2,883 IDR 80
Residual Income 662.49 IDR 850.91 IDR 2,925 IDR 76
Rev-Margin DCF 1,007 IDR 1,580 IDR 2,290 IDR 74
All 26 models by family
DCF Models
FCF DCF 1,078 IDR 1,756 IDR 2,935 IDR 38
Owner Earnings 869.42 IDR 1,390 IDR 2,294 IDR 31
5Y Revenue Exit 1,007 IDR 1,590 IDR 2,363 IDR 39
5Y EBITDA Exit 1,408 IDR 2,387 IDR 3,591 IDR 41
5Y P/E Exit 1,475 IDR 2,521 IDR 3,688 IDR 38
10Y Revenue Exit 996.06 IDR 1,558 IDR 2,380 IDR 36
10Y EBITDA Exit 1,292 IDR 2,143 IDR 3,397 IDR 37
10Y P/E Exit 1,337 IDR 2,242 IDR 3,477 IDR 35
Earnings-Based
Graham-Dodd 667.36 IDR 2,720 IDR 3,702 IDR 54
Lynch FV 681.49 IDR 973.55 IDR 1,266 IDR 50
PEG = 1.0 681.49 IDR 973.55 IDR 1,266 IDR 46
EPV 1,101 IDR 1,263 IDR 1,407 IDR 59
Dividend Discount
Gordon GGM 413.64 IDR 903.05 IDR 1,519 IDR 70
DDM Multi-Stage 413.64 IDR 739.75 IDR 941.13 IDR 61
Multiples
P/E Multiple 1,619 IDR 2,159 IDR 2,699 IDR 63
P/S Multiple 1,013 IDR 1,351 IDR 1,689 IDR 58
P/B Multiple 1,251 IDR 1,668 IDR 2,085 IDR 55
EV/EBIT 1,699 IDR 2,205 IDR 2,710 IDR 53
EV/EBITDA 1,693 IDR 2,197 IDR 2,701 IDR 54
EV/Revenue 992.75 IDR 1,340 IDR 1,688 IDR 43
Asset-Based
NCAV (Graham) 260.83 IDR 349.52 IDR 521.67 IDR 50
Growth DCF
Growth DCF 1,083 IDR 1,739 IDR 2,883 IDR 80
Rev-Margin DCF 1,007 IDR 1,580 IDR 2,290 IDR 74
Economic Profit
Residual Income 662.49 IDR 850.91 IDR 2,925 IDR 76
ROIC Compounder 1,207 IDR 1,536 IDR 1,948 IDR 72
Growth Earnings
Growth-Adj P/E 1,215 IDR 1,736 IDR 2,257 IDR 68

Widest divergence: DCF Models (1,756 IDR) versus Asset-Based (349.52 IDR). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) 5.5T IDR
Revenue growth (YoY) +6.6%
Net margin 25.3%
Return on equity 18.0%
Free cash flow 959B IDR FY2025
P/E ratio 17.2
More key figures
Operating margin 30.1%
EPS (TTM) 99.23 IDR
EPS growth (YoY) +4.8%
Net cash 2.5T IDR FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 71/100

Of which business quality 70 · Market factors (momentum, volatility) 41

Profitability 70
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 65
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 36
Disciplined investing over empire-building
Low Volatility 80
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 27
Distance to the 52-week high (market factor)
Net Issuance 84
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PT Mitra Keluarga Karyasehat Tbk, together with its subsidiaries, owns and operates hospitals in Indonesia. The company also offers healthcare platform services. Its hospital network comprises Mitra Keluarga Hospitals and Kasih Group Hospitals located in Greater Jakarta, West Java, East Java, and Central Java.

Full company description

PT Mitra Keluarga Karyasehat Tbk, together with its subsidiaries, owns and operates hospitals in Indonesia. The company also offers healthcare platform services. Its hospital network comprises Mitra Keluarga Hospitals and Kasih Group Hospitals located in Greater Jakarta, West Java, East Java, and Central Java. The company was founded in 1989 and is headquartered in Jakarta, Indonesia. PT Mitra Keluarga Karyasehat Tbk is a subsidiary of PT Griyainsani Cakrasadaya.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PT Mitra Keluarga Karyasehat Tbk, reported revenue of 5.4T IDR in FY2025 versus 4.4T IDR in FY2021, a compound +5.4%/yr. Reported net income was 1.4T IDR in FY2025, compounding +2.7%/yr from FY2021.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
5.4T IDR
Latest YoY
+10.1%
Avg. growth/yr (3Y)
+9.9%
Avg. growth/yr (5Y)
+9.4%
Avg. growth/yr (13Y)
+10.4%
Revenue +5.4%/yr
FY21 4.4T IDR
FY22 4.0T IDR
FY23 4.3T IDR
FY24 4.9T IDR
FY25 5.4T IDR
Net income +2.7%/yr
FY21 1.2T IDR
FY22 1.0T IDR
FY23 916B IDR
FY24 1.1T IDR
FY25 1.4T IDR

Watch MIKA: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "PT Mitra Keluarga Karyasehat Tbk, Fair Value". https://www.fairvalue-calculator.com/stock/MIKA

Peer Group

Medical Care Facilities · 262 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 71 · Top 25%
Fair Value upside +13% · Above median
Return on equity (TTM) 18% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 25% · Top 25%
Operating margin (TTM) 30% · Top 25%
Revenue growth 7% · Above median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.00× · Lower than 75% of peers

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 17.2× · Cheaper than median
P/B 3.27× · Pricier than 75% of peers
P/S (TTM) 4.35× · Pricier than 75% of peers
P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 10.3× · Pricier than median
PEG 1.41× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 51 · sector 22
FUTURE 33 · sector 24
PAST 72 · sector 30
HEALTH 100 · sector 90
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare PT Mitra Keluarga Karyasehat Tbk, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is PT Mitra Keluarga Karyasehat Tbk, (MIKA) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of 2,143 IDR versus a price of 1,890 IDR, about +13% (undervalued).
What is the fair value of MIKA?
Our model-based fair value for PT Mitra Keluarga Karyasehat Tbk, is 2,143 IDR (as of Jul 12, 2026), built from audited fundamentals. The current price is 1,890 IDR.
What is the quality score of MIKA?
PT Mitra Keluarga Karyasehat Tbk, has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PT Mitra Keluarga Karyasehat Tbk, (MIKA)?
PT Mitra Keluarga Karyasehat Tbk, reported trailing-twelve-month revenue of about 5.5T IDR (latest available figure, as of Jul 12, 2026).
What is the net profit margin of MIKA?
The net profit margin of PT Mitra Keluarga Karyasehat Tbk, is about 25.3%, meaning it keeps roughly 25.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PT Mitra Keluarga Karyasehat Tbk, and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.